Buscar
Altimmune Inc
ALTAñadir a la lista de seguimiento
2.840USD
-0.140-4.70%
Cierre 07-31 16:00（ET）Cotizaciones retrasadas 15 min
552.31MCap. mercado
PérdidaP/E TTM
Más Datos de Altimmune Inc Compañía
Altimmune, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing next-generation peptide-based therapeutics. It is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity, metabolic dysfunction-associated steatohepatitis (MASH) and other indications. Activation of the GLP-1 and glucagon receptors is believed to mimic the complementary effects of diet and exercise on weight loss, with GLP-1 suppressing appetite and glucagon increasing energy expenditure. Glucagon is also recognized as having direct effects on hepatic fat metabolism, to rapid reductions in levels of liver fat and serum lipids. The Company has completed the MOMENTUM Phase II obesity trial and is being studied in the IMPACT Phase IIb MASH trial. The Company also develops and commercializes surfactant-functionalized (EuPort domain) incretin-based peptide therapeutics, including (GLP-1-glucagon)/oxyntomodulin, and variants.
Información de Altimmune Inc
Símbolo de cotizaciónALT
Nombre de la empresaAltimmune Inc
Fecha de salida a bolsaOct 06, 2005
Director ejecutivoDurso (Jerome Benedict)
Número de empleados59
Tipo de seguridadOrdinary Share
Fin del año fiscalOct 06
Dirección910 Clopper Road
CiudadGAITHERSBURG
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal20878-1361
Teléfono12406541450
Sitio Webhttps://altimmune.com/
Símbolo de cotizaciónALT
Fecha de salida a bolsaOct 06, 2005
Director ejecutivoDurso (Jerome Benedict)
Ejecutivos de Altimmune Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Vipin K. Garg, Ph.D.
Dr. Vipin K. Garg, Ph.D.
Director
Director
424.52K
+16.36%
Mr. Raymond M. (Ray) Jordt
Mr. Raymond M. (Ray) Jordt
Chief Business Officer
Chief Business Officer
70.11K
+48.26%
Mr. Jerome Benedict (Jerry) Durso
Mr. Jerome Benedict (Jerry) Durso
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
47.50K
+31.58%
Mr. Gregory L. (Greg) Weaver
Mr. Gregory L. (Greg) Weaver
Chief Financial Officer
Chief Financial Officer
38.08K
+26.26%
Dr. Mitchel B. (Mitch) Sayare, Ph.D.
Dr. Mitchel B. (Mitch) Sayare, Ph.D.
Independent Director
Independent Director
26.36K
--
Mr. John M. Gill
Mr. John M. Gill
Independent Director
Independent Director
21.70K
+42.40%
Brig. Gen. (Retd.) Klaus O. Schafer, M.D.
Brig. Gen. (Retd.) Klaus O. Schafer, M.D.
Independent Director
Independent Director
9.18K
--
Dr. Catherine Angell Sohn, Pharm.D.
Dr. Catherine Angell Sohn, Pharm.D.
Independent Director
Independent Director
1.50K
--
Dr. Diane K. Jorkasky, M.D.
Dr. Diane K. Jorkasky, M.D.
Independent Director
Independent Director
527.00
--
Dr. M. Scot Roberts, Ph.D.
Dr. M. Scot Roberts, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Vipin K. Garg, Ph.D.
Dr. Vipin K. Garg, Ph.D.
Director
Director
424.52K
+16.36%
Mr. Raymond M. (Ray) Jordt
Mr. Raymond M. (Ray) Jordt
Chief Business Officer
Chief Business Officer
70.11K
+48.26%
Mr. Jerome Benedict (Jerry) Durso
Mr. Jerome Benedict (Jerry) Durso
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
47.50K
+31.58%
Mr. Gregory L. (Greg) Weaver
Mr. Gregory L. (Greg) Weaver
Chief Financial Officer
Chief Financial Officer
38.08K
+26.26%
Dr. Mitchel B. (Mitch) Sayare, Ph.D.
Dr. Mitchel B. (Mitch) Sayare, Ph.D.
Independent Director
Independent Director
26.36K
--
Mr. John M. Gill
Mr. John M. Gill
Independent Director
Independent Director
21.70K
+42.40%
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Altimmune Inc?
Los cinco principales accionistas de Altimmune Inc son: Dr. Vipin K. Garg, Ph.D.
¿Cuántas instituciones poseen acciones de Altimmune Inc (ALT)?
A fecha de 2026Q1, 416 instituciones poseen acciones de Altimmune Inc, con un valor de mercado combinado de aproximadamente 57.72M, lo que representa el 30.53% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 4635873.00.